Skip to main content
All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for HALEON US HOLDINGS LLC · consumer health care company

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · New Jersey · House · Senate · $50,000.00 income · posted Jan 19, 2026

Official filing document

 Bills named in this filing 5
  • HR 4273
    Over-the-Counter Monograph Drug User Fee Amendments
  • S 2292
    Over-the-Counter Monograph Drug User Fee Amendments
  • HR 5371
    Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions …
  • HR 5166
    Financial Services and General Government Appropriations Act, 2026
  • S 3290
    Financial Services and General Government Appropriations Act, 2026
 Lobbying activity 4
Health Issues

Issues related to healthcare and payment for over-the-counter drugs; General education of over-the-counter switches, including reauthorization of the Over-the-Counter Monograph Drug User Fee Act and policies impacting a Nonprescription Drug Product with an Additional Condition for Nonprescription Use; H.R.4273/S.2292, Over-the-Counter Monograph Drug User Fee Amendments; FY2026 Continuing Appropriations and Extensions Act (H.R.5371/P.L.119-37).

Taxation/Internal Revenue Code

Issues related to coverage of over-the-counter products with FSAs and HSAs.

Budget/Appropriations

Policies impacting access to over-the-counter products; FY2026 Financial Services and General Government Appropriations Act process (H.R.5166/S.3290).

Trade (domestic/foreign)

Policies impacting the supply chain and manufacturing of over-the-counter pharmaceutical products including tariffs.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem